We were incorporated under the laws of the Commonwealth of Australia on May 21, 1987. Immutep, formerly called Prima BioMed, was originally created as a mining company (Prima Resources) in Australia in 1987 and was first publicly traded in 1988 on the Australian Stock Exchange.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Partnerships Merck & Co./MSD (3 clinical trial collaboration and supply agreements for efti + pembrolizumab in Phase II and Phase III trials); Merck KGaA + Pfizer (2 agreements for efti + avelumab in Phase I trials); EOC Pharma (licensee for efti development and manufacturing in China)
Status note Most advanced of five LAG-3 programs. Soluble LAG-3 immune activator used with other therapies to amplify immune response. Specific cancer indications not stated in the filing excerpts.
IMP701
Stage not disclosed · Active
Aliases LAG525, ieramilimab
Target LAG-3
Partnerships Novartis (fully licensed to CoStim Pharmaceuticals, subsequently acquired by Novartis)
Status note Licensed out; stage and indications not stated in filing excerpts.
IMP731
Stage not disclosed · Active
Aliases GSK'781
Target LAG-3
Partnerships GSK
Status note Partnered with GSK; stage and indications not stated in filing excerpts.
anti-LAG-3 small molecule program
Discovery · ActiveModality: small molecule
Target LAG-3
Status note Described as a very early stage anti-LAG-3 small molecule program.
IMP761
Stage not disclosed · ActiveModality: antibody
Target LAG-3
Indications
autoimmune disease(Stage not disclosed)
Status note Clinical-stage agonist antibody of LAG-3 for application in autoimmune disease; exact phase not stated in filing excerpts.
Per-asset detail extracted from the 20-F filed 2025-10-24. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Latest news
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.
Get the weekly biotech catalyst rundown. Cash runways, financings, and trial readouts for all 721 stocks.